Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRO: ANPD001 in Sporadic Parkinson Disease
NCT06344026Phase 1Enrolling by invitation
- Sponsor
- Aspen Neuroscience
- Start
- Jan 2024
- Primary completion
- Mar 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ANPD001 in Parkinson's disease (PD), sponsored by Aspen Neuroscience. Primary endpoint: Incidence and severity of treatment emergent adverse events at 1 year. Started Jan 2024; status: enrolling by invitation.
02
Drugs
ANPD001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06344026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344026.